Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIPG-DC
- Development stage
- Phase 1
- Lead developer
- Fundació Sant Joan de Déu
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
DIPG-DC is an experimental autologous dendritic cell vaccine developed by Fundacio Sant Joan De Deu for the treatment of diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric brain tumor. The manufacturing process involves isolating a patient's monocytes, differentiating them into dendritic cells, and pulsing them with a lysate derived from three specific DIPG cell lines (HSJD-DIPG-007, HSJD-DIPG-008, and HSJD-DIPG-011). These matured dendritic cells are then injected intradermally back into the patient, where they migrate to lymph nodes and present tumor-specific antigens to T-lymphocytes. This process is designed to bypass the tumor's immune evasion mechanisms and induce a robust, targeted anti-tumor immune response.
- Other names
- DIPG dendritic cell vaccineAutologous dendritic cell vaccine for DIPG
02
Targets
γδ TCR (T-cell receptor)Tumor-associated antigens from diffuse intrinsic pontine glioma (DIPG) lysate presented by major histocompatibility complex (MHC) class I/II
Beyond the preview
Go deeper on DIPG-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIPG-DC.